BridgeBio Pharma, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BridgeBio Pharma, Inc. (BBIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $45.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $45.42M, a 19.24% increase year-over-year.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $32.78M, a 2.27% increase year-over-year.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $35.63M, a 33.71% increase year-over-year.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $38.09M, a 20.90% increase year-over-year.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $140.17M, a 25.15% increase from fiscal 2024.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $112.00M, a 13.59% increase from fiscal 2023.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $98.60M, a 4.70% increase from fiscal 2022.
- BridgeBio Pharma, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $94.17M, a 4.84% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 1 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $45.42M 10-Q · filed 2026-08-10 | $78.20M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $32.78M 10-Q · filed 2026-08-10 | ||||
| 2025-12-31 | $140.17M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $35.63M 10-Q · filed 2025-10-29 | $73.72M derived: sum of 2 quarters · filed 2026-08-10 | $105.78M derived: sum of 3 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $38.09M 10-Q · filed 2026-08-10 | $70.15M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $32.06M 10-Q · filed 2026-08-10 | ||||
| 2024-12-31 | $112.00M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $26.65M 10-Q · filed 2025-10-29 | $58.15M derived: sum of 2 quarters · filed 2025-10-29 | $85.28M derived: sum of 3 quarters · filed 2025-10-29 | ||
| 2024-06-30 | $31.50M 10-Q · filed 2025-10-29 | $58.63M derived: sum of 2 quarters · filed 2025-10-29 | |||
| 2024-03-31 | $27.13M 10-Q · filed 2025-10-29 | ||||
| 2023-12-31 | $98.60M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $24.23M 10-Q · filed 2024-11-12 | $48.85M derived: sum of 2 quarters · filed 2024-11-12 | $73.18M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $24.61M 10-Q · filed 2024-11-12 | $48.94M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $24.33M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $94.17M 10-K · filed 2025-02-20 | ||||
| 2022-09-30 | $23.23M 10-Q · filed 2023-11-02 | $47.13M derived: sum of 2 quarters · filed 2023-11-02 | $72.56M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $23.90M 10-Q · filed 2023-11-02 | $49.32M derived: sum of 2 quarters · filed 2023-11-02 | |||
| 2022-03-31 | $25.42M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $89.82M 10-K · filed 2024-02-22 | ||||
| 2021-09-30 | $16.90M 10-Q · filed 2022-11-03 | $49.41M derived: sum of 2 quarters · filed 2022-11-03 | $69.25M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $32.51M 10-Q · filed 2022-11-03 | $52.35M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $19.84M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $36.53M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $11.75M 10-Q · filed 2021-11-04 | $19.04M derived: sum of 2 quarters · filed 2021-11-04 | $27.11M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $7.29M 10-Q · filed 2021-11-04 | $15.36M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $8.06M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $15.20M 10-K · filed 2022-02-25 | ||||
| 2019-06-30 | $69.00K 10-Q · filed 2019-08-14 | ||||
| 2018-12-31 | $3.18M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |